^
    2d
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (clinicaltrials.gov)
    P1/2, N=30, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    3d
    A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | N=27 --> 0 | Enrolling by invitation --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide
    8d
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. (PubMed, Cancers (Basel))
    Nadofaragene firadenovec, a recombinant adenovirus delivering interferon alpha-2b (IFNα2b), is the first FDA-approved gene therapy for BCG-unresponsive NMIBC with carcinoma in situ (CIS)...Cretostimogene grenadenorepvec (CG0070), an oncolytic vector, demonstrated a 47% 6-month CR rate in a phase II study (NCT02365818). Detalimogene voraplasmid (EG-70), a nonviral gene therapy, demonstrated a 47% 6-month CR in a phase I/II study (NCT04752722). Future advances are likely to focus on patient selection, novel vectors, and combination strategies to improve treatment outcomes. Gene therapy represents a significant addition to the bladder cancer treatment landscape by offering bladder-sparing alternatives where conventional therapies are limited.
    Review • Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Adstiladrin (nadofaragene firadenovec-vncg) • cretostimogene grenadenorepvec (CG0070) • detalimogene voraplasmid (EG-70)
    9d
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=12, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> May 2026
    Trial completion date • Trial primary completion date
    13d
    A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, ImmVira Pharma Co. Ltd
    New P1/2 trial
    |
    MVR-C5252
    15d
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    1m
    A Clinical Study of T3011 Bladder Perfusion in Patients with High-risk Non-muscle-invasive Bladder Cancer (ChiCTR2500109273)
    P=N/A, N=15, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    T3011
    1m
    KYANITE-1: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (clinicaltrials.gov)
    P1/2, N=250, Recruiting, Krystal Biotech, Inc. | Trial completion date: Feb 2028 --> Jul 2028 | Trial primary completion date: Feb 2028 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • docetaxel
    2ms
    ANK-101-004: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Ankyra Therapeutics, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cetrelimab (JNJ-63723283)
    2ms
    A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, ImmVira Pharma Co. Ltd | N=64 --> 30 | Trial completion date: Oct 2025 --> Jan 2027 | Trial primary completion date: Oct 2023 --> Sep 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • T3011
    2ms
    M032-HSV-1: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Sep 2025 --> Sep 2027
    Trial completion date
    2ms
    Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial. (PubMed, Nat Commun)
    These findings support continued clinical development of tolododekin alfa. ClinicalTrials.gov registration: NCT06171750.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression